Dr Bridges added in a separate press release statement: “We are now confident that providers can recommend biosimilars as a safe, effective, and affordable option to patients, where appropriate.” Presently, the FDA has approved 9 biosimilar products. Six of these have indications for rheumatic diseases.
Washington, DC—On March 7, 2018, FDA Commissioner Scott Gottlieb, MD, delivered a speech to attendees of the America’s Health Insurance Plans National Health Policy Conference that called out pharmacy benefit managers (PBMs) for their role in disincentivizing biosimilar development.
Recent Analysis Supports the Interchangeability of Biosimilar TNF-α Inhibitors and Their Respective Reference Drugs
London, United Kingdom—Monitoring antidrug antibody formation in those receiving biologic disease-modifying antirheumatic drugs can inform treatment decisions in patients with rheumatic diseases. In particular, patients who developed antibodies to infliximab (Remicade) cross-reacted with the infliximab biosimilar CT-P13—marketed as Remsima or Inflectra—according to data from a multicenter, controlled study of patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA) presented at the 2016 European League Against Rheumatism Annual Congress.
Results 1 - 5 of 5